APP and Parkinson disease: The molecular mechanism revealed that rTMS results in the reduction of APP through the inhibition of the MKK7-ERK1/2-c-FOS-APP axis in a 6-OHDA-induced mouse model of Parkinson’s disease (Figure 3) [59,60,61].